FY3Q19 royalty revenue=$44.4M, up from $39.6M in FY2Q19 (Jan-Mar 2019).
ENTA’s royalty rate from ABBV resets to the lowest tier at the start of each calendar year; the royalty tiers applicable to the 50% Glecaprevir component of Mavyret are shown in #msg-142808661.
ENTA’s 6/30/19 cash balance=$389.2M.
FY3Q19 GAAP EPS=$0.33 (including an $0.04 tax credit).